ZA200104931B - Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body. - Google Patents

Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body.

Info

Publication number
ZA200104931B
ZA200104931B ZA200104931A ZA200104931A ZA200104931B ZA 200104931 B ZA200104931 B ZA 200104931B ZA 200104931 A ZA200104931 A ZA 200104931A ZA 200104931 A ZA200104931 A ZA 200104931A ZA 200104931 B ZA200104931 B ZA 200104931B
Authority
ZA
South Africa
Prior art keywords
constriction
organs
prevention
treatment
composition
Prior art date
Application number
ZA200104931A
Other languages
English (en)
Inventor
Matthias Rath
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of ZA200104931B publication Critical patent/ZA200104931B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA200104931A 2000-06-16 2001-06-15 Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body. ZA200104931B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00112811A EP1163904B1 (en) 2000-06-16 2000-06-16 Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium

Publications (1)

Publication Number Publication Date
ZA200104931B true ZA200104931B (en) 2001-12-20

Family

ID=8168995

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200104931A ZA200104931B (en) 2000-06-16 2001-06-15 Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body.

Country Status (23)

Country Link
EP (1) EP1163904B1 (ja)
JP (1) JP2002047183A (ja)
KR (1) KR100793573B1 (ja)
CN (1) CN1245973C (ja)
AT (1) ATE323479T1 (ja)
AU (1) AU780906C (ja)
BR (1) BR0103256A (ja)
CA (1) CA2350713C (ja)
CZ (1) CZ20012178A3 (ja)
DE (1) DE60027415T2 (ja)
DK (1) DK1163904T3 (ja)
ES (1) ES2258426T3 (ja)
HK (1) HK1043947A1 (ja)
HU (1) HUP0102489A2 (ja)
IL (1) IL143697A (ja)
NO (1) NO20013004L (ja)
PL (1) PL348097A1 (ja)
PT (1) PT1163904E (ja)
RU (1) RU2280441C2 (ja)
SK (1) SK285454B6 (ja)
TR (1) TR200101673A2 (ja)
UA (1) UA77147C2 (ja)
ZA (1) ZA200104931B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1163904E (pt) * 2000-06-16 2006-07-31 Rath Matthias Composicao para a prevencao de doencas do musculo liso, compreendendo ascorbato, arginina e magnesio
US6576634B1 (en) * 2000-07-07 2003-06-10 N.V. Nutricia Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality
US6372264B1 (en) * 2000-08-24 2002-04-16 Gusty Winds Corporation Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
WO2002024002A2 (en) * 2000-09-22 2002-03-28 Mars Uk Limited Food supplement
UA77660C2 (en) 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
AUPS019802A0 (en) * 2002-01-31 2002-02-21 Chemstop Pty Ltd Nutrient formulation
AU2003239154B2 (en) * 2002-01-31 2007-02-01 Chemstop Pty Ltd Process for the preparation of a nutrient formulation
GB0202900D0 (en) 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
CN1655815A (zh) * 2002-05-20 2005-08-17 切姆斯托普有限公司 物质的制备及活化方法及其制备设备
ATE464043T1 (de) * 2002-08-22 2010-04-15 Vasopharm Biotech Gmbh Pharmazeutische zusammensetzung enthaltend l- arginin
US9655966B2 (en) * 2002-08-28 2017-05-23 Kedar N. Prasad Micronutrient formulations for radiation applications
WO2004069822A1 (ja) * 2003-02-05 2004-08-19 Santen Pharmaceutical Co., Ltd. ステロイド副作用抑制組成物
EP2397128A1 (en) * 2003-02-14 2011-12-21 Children's Hospital & Research Center at Oakland Use of L-arginine optionally combined with magnesium for the treatment of sickle cell disease and/or pulmonary hypertension
CA2524381A1 (en) * 2003-05-30 2004-12-16 Matthias Rath Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
JP2007530607A (ja) * 2004-03-30 2007-11-01 ユニリーバー・ナームローゼ・ベンノートシヤープ ビタミンおよびフラボノイドを含むスキンライトニング組成物
FR2884692B1 (fr) * 2005-04-21 2009-08-14 Formquest Ltd Complement alimentaire comprenant une association d'agents antioxydants et de carnitine, obtenue par synthese endogene ou exogene, comme aide a la fertilite chez l'homme et chez la femme
FR2884691B1 (fr) * 2005-04-21 2007-07-20 Formquest Ltd Complement alimentaire comprenant une combinaison d'agents antioxydants et d'agents energisants utile comme aide a la fertilite chez l'homme et chez la femme
US7754700B2 (en) 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
EP2253307B1 (de) * 2006-05-12 2015-07-08 Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG L-Carnitin zur Kristallisationshemmung
EP1862163A1 (de) 2006-05-12 2007-12-05 Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG L-Carnitin zur Kristallisationsverzögerung
RU2315612C1 (ru) * 2006-08-29 2008-01-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Средство для лечения заболеваний глаз
JP5878016B2 (ja) * 2009-09-18 2016-03-08 株式会社明治 筋拘縮予防剤
AT510810B1 (de) * 2010-12-09 2017-09-15 Gonadosan Gmbh Kombinationspräparat zur verbesserung der weiblichen fertilität
JP2013049670A (ja) * 2011-08-04 2013-03-14 Fancl Corp アスコルビン酸製剤
EP3160459A1 (en) * 2014-06-24 2017-05-03 Dedraf Holding B.V. New mineral composition
CN104688774A (zh) * 2015-02-17 2015-06-10 胡梨芳 包含手性异构化合物的赖氨酸磷酸氢钙药物组合物及其用途
CN105687204B (zh) * 2016-04-15 2018-05-25 石家庄东华金龙化工有限公司 一种甘氨酸金属螯合物复合物及其制备方法
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
CN108685754A (zh) * 2018-07-30 2018-10-23 郑州兰茜生物工程有限公司 一种用于耳鸣及具有健耳舒耳功能的滴耳剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5198465A (en) * 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
EP0891771A1 (en) * 1997-07-08 1999-01-20 Health Now, Inc. Compositions comprising lysine and ascorbate compounds for the treatment and prevention of cardiovascular diseases
AU3221599A (en) * 1998-04-03 1999-10-25 Daily Wellness Company, The Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
GB9922751D0 (en) * 1999-09-27 1999-11-24 Kenton Corp Limited A pharmaceutical composition for stabilising atherosclerotic plaques
PT1163904E (pt) * 2000-06-16 2006-07-31 Rath Matthias Composicao para a prevencao de doencas do musculo liso, compreendendo ascorbato, arginina e magnesio

Also Published As

Publication number Publication date
AU780906C (en) 2006-04-27
ES2258426T3 (es) 2006-09-01
AU5194201A (en) 2001-12-20
HUP0102489A2 (hu) 2003-11-28
TR200101673A2 (tr) 2002-02-21
SK8232001A3 (en) 2002-01-07
HK1043947A1 (en) 2002-10-04
DK1163904T3 (da) 2006-08-14
PT1163904E (pt) 2006-07-31
DE60027415T2 (de) 2006-10-19
NO20013004D0 (no) 2001-06-15
ATE323479T1 (de) 2006-05-15
SK285454B6 (sk) 2007-01-04
AU780906B2 (en) 2005-04-21
CZ20012178A3 (cs) 2002-04-17
EP1163904A1 (en) 2001-12-19
CA2350713A1 (en) 2001-12-16
UA77147C2 (en) 2006-11-15
EP1163904B1 (en) 2006-04-19
NO20013004L (no) 2001-12-17
PL348097A1 (en) 2001-12-17
KR20010113499A (ko) 2001-12-28
CN1245973C (zh) 2006-03-22
BR0103256A (pt) 2002-03-12
JP2002047183A (ja) 2002-02-12
CN1333020A (zh) 2002-01-30
IL143697A0 (en) 2002-04-21
RU2280441C2 (ru) 2006-07-27
IL143697A (en) 2006-12-10
DE60027415D1 (de) 2006-05-24
CA2350713C (en) 2007-01-16
KR100793573B1 (ko) 2008-01-14

Similar Documents

Publication Publication Date Title
ZA200104931B (en) Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body.
WO2004047747A3 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
WO2002078644A3 (en) Use of ozone for the treatment of dental and oral conditions
IL187512A0 (en) Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence
WO2001052921A3 (en) Valve arrangement
IL159527A0 (en) Human dr4 antibodies and uses thereof
DE60330693D1 (de) WuRMEBEHANDLUNGSVERFAHREN UND WuRMEBEHANDLUNGSVORRICHTUNG
MY164077A (en) Compositions and uses of et743 for treating cancer
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
EP1404281A4 (en) TOPICAL USE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND / OR MUCOSAL LESIONS, USE OF COMPOSITIONS AND COMPOUNDS IN THE TREATMENT OF SKIN AND / OR MUCOUS DISEASES
NO20043614L (no) 2`-halogen-3`,5`-dialkoksyfen-1`-yl-imino-2-imidazolid in-derivater og anvendelse derav for behandling av urin-inkontinens
IL150527A0 (en) Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
SG106614A1 (en) Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body
NZ512402A (en) Vitamin C and other vitamin derivatives, arginine and other amino acids and magnesium and other trace elements used in the treatment of conditions caused by smooth muscle construction e.g. tinnitus and asthma bronchiale
PL355292A1 (en) Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
AU2003240254A8 (en) Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
AU2001262773A1 (en) Novel oligonucleotide compounds having pyrrolizine derivatives, processes fro preparing them, compositions containing them and uses thereof in treatment, diagnosis and analysis of gene-related diseases
AU2002217110A1 (en) Fractions of snake blood, their preparation and use as therapeutic agents
MXPA03004074A (es) Derivados de retiferol y su uso en el tratamiento de enfermedades o trastornos de la piel asociadas con fotoda°o.
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин
UA5430S (uk) Комплекс лікувально-тренувальний офтальмологічний
UA36521A (uk) Спосіб здійснення реабілітаційно-оздоровчих технологій, що передбачають корегування функціонального стану організму пацієнта проведенням процедур біоадаптивного керування з використанням біологічного зворотного зв'язку,та апаратний комплекс для його здій
UA36524A (uk) Спосіб проведення реабілітаційно-оздоровчих процедур, що засновані на використанні біологічного зворотного зв'язку, та апаратний комплекс для його здійснення
SI1196159T1 (en) Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues